Glecaprevir/pibrentasvir (GLE/PIB) is a fixed-dose combination therapy approved for hepatitis C virus (HCV) that has expanded reach, reduced cost, and in certain patient populations, reduced HCV treatment duration, according to a recent review. The authors concluded:
- GLE/PIB is effective across all genotypes.
- GLE/PIB has been shown to be effective in HIV-infected patients, patients with chronic kidney disease (CKD), and Child-Pugh A-compensated cirrhosis.
- GLE/PIB is also effective for a shortened duration of 8 weeks in treatment-naïve non-cirrhotic patients.
Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. [Published online ahead of print May 29, 2018]. Hepatol Int. doi:10.1007/s12072-018-9873-y.
This Week's Must Reads
Increased Water Intake in Premenopausal Women with UTIs, JAMA Intern Med; ePub 2018 Oct 1; Hooton, et al
Adverse Childhood Experiences & Weight Status, J Pediatr; ePub 2018 Oct 1; Davis, Barnes, et al
Prevalence of E-Cigarette Use Among US Adults, Ann Intern Med; 2018 Oct 2; Mirbolouk, et al
Continuous Combined Oral Contraceptives & VTE Risk, JAMA Intern Med; ePub 2018 Oct 1; Li, et al
Wearable Cardioverter-Defibrillator Use After MI, N Engl J Med; 2018 Sep 27; Olgin, et al
Must Reads in Hepatitis
Limited Coverage of HCV Testing in US Since 2013, Clin Infect Dis; ePub 2018 Sep 15; Patel, et al
Smoking Status & Pain in Veterans with HCV, Pain Med; ePub 2018 Sep 7; Lynch, et al
Assessing the HCV Care Cascade in Baby Boomers, Am J Manag Care; 2018 Sep; Brady, Vellozzi, et al
HCV Screening in Elective Cranial Neurosurgery, J Neurosurg; 2018 Sep; Nussbaum, Kallmes, et al
Young Adults Who Inject Drugs & Risk of HCV, Health Promot Pract; ePub 2018 Sep 18; Knight, et al